]. The effect on RNA polymerase IIspecific transcription seems to be mediated by its inhibition of nuclear casein kinase II [Zandomeni, CarreraZandomeni, Shugar & Weinmann (1986) J. Biol. Chem. 261, 3414-3419]. Inhibition studies indicated that DRB acted as a mixed-type inhibitor with respect to casein and as a competitive inhibitor with respect to the nucleotide phosphate donor substrates. The DRB inhibition constant is 7 ,uM for the calf thymus casein kinase II, with regard to both ATP and GTP.
INTRODUCTION
By using 5,6-dichloro-1 -f-D-ribofuranosylbenzimidazole (DRB), an analogue of adenosine, it has been possible to establish the involvement of casein kinase II during RNA polymerase II transcription (Zandomeni & Weinmann, 1984) . This compound inhibits specific cellular RNA polymerase II transcription without directly affecting other cellular functions (Tamm & Sehgal, 1978) . DRB inhibits both specific RNA polymerase II transcription and the casein kinase II contained in the same extracts at identical concentrations (Zandomeni & Weinmann, 1984) . When transcription reaction mixtures in vitro inhibited with DRB were supplemented with excess pure casein kinase II, the inhibition was partially overcome (Zandomeni et al., 1986) . Unphosphorylated phosvitin was able to inhibit transcription after microinjection of Chironomus cells, whereas phosphorylated phosvitin was not. Presumably, all casein kinase II activity was shunted to this exogenous substrate and was thus unable to participate in the transcription process (Egyhazi & Pigon, 1986) . Thus, although the phosphorylation targets for casein kinase within the transcriptional machinery have not yet been identified, the role of this enzyme in the DRB inhibition of specific transcription in vitro appears to be well established (Egyhazi & Pigon, 1986; Zandomeni et al., 1986) .
Since the target for the DRB inhibition appears to be casein kinase II and this enzyme can be readily purified, it becomes important to establish the type of inhibition and its kinetic parameters. Casein kinase II can use either ATP or GTP as a phosphate donor. We have developed a rapid purification procedure for the calf thymus enzyme (Zandomeni et al., 1986 Active fractions were pooled and diluted with buffer A to a concentration of 280 mM-NaCl and loaded on to a 1 ml Mono-Q anion-exchange column pre-equilibrated with 280 mM-NaCl in buffer A. After a 20 ml wash, the kinase activity was eluted with a linear gradient of 280-500 mM-NaCl in buffer A. The run was performed at 4°C with a 0.2 ml/min flow rate.
Data analysis
Data from duplicate reactions for initial-velocity studies were plotted in double-reciprocal form. The kinetic constants were determined from the slope and intercept replots of the initial-velocity data. For the calculation of inhibition constants, the slopes and intercepts of the primary double-reciprocal plots at each concentration of the relevant substrate were plotted against the inhibitor concentrations, and the curves were calculated by the least-squares fit method. All the kinase studies were carried out with homogeneous casein kinase II purified as described. The kiia-se was more than-98 % pure and was used at a concentration of 2 nm (assuming an Mr of 170000) in all reactions. Partially hydrolysed and dephosphorylated casein was used as a protein phosphate acceptor, and ATP or GTP was used as the phosphate donor as indicated. (Sehgal, 1975) Fig. 5 . To calculate /3, the factor reflecting how the binding of DRB affects the binding of casein, the 1/v axis intercepts (from Fig. 5 ) and the other reciprocal plots at different concentrations of GTP versus DRB concentration were replotted (Fig. 6) . The vertical co-ordinate of the intersection point of the family of lines (each line represents a different concentration of GTP) corresponds to 1/ Vmax. The Vnax calculated from Fig. 6 was I /,mol/min per mg, in agreement with the value calculated in the kinetic analysis ( Figs. 1 and 2) . A secondary replot (Fig. 6 inset) shows the intercepts of the projection of each line with the horizontal axis (from ),l10O/LM (U)
RESULTS
The fact that DRB competes with ATP and GTP means that inhibition by this drug will not be observed whenever there is a high concentration of ATP and GTP, as there is in the nucleus (Rapaport et al., 1979) . However, since DRB is able to inhibit nuclear protein phosphorylation in vivo (Egyhazi & Pigon, 1983; Zandomeni & Weinmann, 1984) , the conditions in nuclei must be such that casein kinase II activity is still diminished by the drug even when ATP and GTP concentrations are high. A solution to this contradiction may rest in the high concentration of ADP and GDP in nuclei (Rapaport, 1980) . ADP and GDP, as products of the phosphotransferase reaction (Scheme 1), act as competitive inhibitors with regard to the phosphate donor (Glover et al., 1983 kinase II activity (Dahmus, 1976; Maenpaa, 1977; Rapaport, 1980; Feige et al., 1980; Farron-Furstenthal, 1980) (Egyhazi & Pigon, 1986) and in vitro (Zandomeni et al., 1986 (Rapaport, 1980) . Thus the specific transcription system in vitro seems to reproduce the nuclear environment in which DRB inhibition of protein phosphorylation and RNA polymerase II transcription are possible. Furthermore, greater DRB inhibition of specific transcription in vitro was always observed at low concentrations of ATP and GTP. In the cell, variations of ADP and GDP concentration due to ATPases or GTPases could regulate the total casein kinase II activity, and, indirectly, the extent of RNA polymerase II transcription. These may be additional points of regulation of mRNA synthesis in eukaryotic cells. Further studies are needed to determine whether cells can regulate transcription by regulating casein kinase II activity.
